Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200417 · ClinicalTrials.gov registry record · Phase 1
Chemoembolization for Lung Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04200417: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04200417 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04200417, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
Interventions
- DRUG Mitomycin C
- DRUG Lipiodol
- PROCEDURE Chemoembolization
- DRUG Embospheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2022-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04200417
The ClinicalTrials.gov registry entry for NCT04200417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mitomycin C is the first listed.
NCT04200417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04200417 about?
NCT04200417 is a clinical study titled "Chemoembolization for Lung Tumors". This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.
What is the current status of trial NCT04200417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-12-13. Estimated completion is 2022-04-19.
What interventions are being tested in trial NCT04200417?
The interventions under investigation include: Mitomycin C (DRUG), Lipiodol (DRUG), Chemoembolization (PROCEDURE), Embospheres (DRUG).
Who is sponsoring clinical trial NCT04200417?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.